Dr. Reddy's Secures Delhi High Court Victory in Semaglutide Patent Dispute
The Delhi High Court Division Bench confirmed Dr. Reddy's Laboratories' permission to manufacture semaglutide in India and export to countries where Novo Nordisk lacks patent registration, marking a significant legal victory in their ongoing pharmaceutical patent dispute.
*this image is generated using AI for illustrative purposes only.
The Delhi High Court Division Bench has upheld Dr. Reddy's Laboratories permission to manufacture and export semaglutide, delivering a significant legal victory for the Indian pharmaceutical company in its ongoing patent dispute with Danish drugmaker Novo Nordisk.
Division Bench Confirms Manufacturing Rights
Through its judgment dated March 09, 2026, the Division Bench of Delhi High Court upheld the previous Single-Judge Bench's order that permitted the company to manufacture semaglutide in India. The court specifically allowed exports to countries where Novo Nordisk does not hold patent registration, while refusing to grant an interim injunction on semaglutide containing products.
| Court Decision Details: | Information |
|---|---|
| Judgment Date: | March 09, 2026 |
| Court Level: | Division Bench (Appeal) |
| Previous Order: | Single-Judge Bench Permission |
| Export Scope: | Non-patent countries only |
| Interim Injunction: | Refused |
Official Company Disclosure
Dr. Reddy's Laboratories issued an official disclosure on March 10, 2026, pursuant to Regulation 30(11) of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company clarified that the news pertains to an ongoing interim injunction proceeding involving semaglutide containing products.
Patent Dispute Context
The legal battle centers around semaglutide, a crucial medication used in diabetes and obesity treatment. The dispute involves an interim injunction proceeding between Dr. Reddy's Laboratories and Novo Nordisk, with the matter remaining sub-judice. The company noted that at this stage, there is no material event or information requiring disclosure under Regulation 30 of the SEBI Listing Regulations.
Business Impact and Market Access
The court's decision provides Dr. Reddy's with a clear legal framework to continue manufacturing operations in India while enabling strategic export opportunities to markets where Novo Nordisk lacks patent protection. This ruling represents an important development for the company's pharmaceutical operations in the high-value diabetes and obesity treatment segment, allowing continued business activities during the ongoing litigation process.
15
